Abstract 1130: First-in-class KAT6A/KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER+ breast cancer with KAT6A dysregulationShikhar Sharma, Thomas A. Paul, Natalie Nady et al.|Cancer Research|2021Cited by 14
First-in-class KAT6A/KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER plus breast cancer with KAT6A dysregulation.Shikhar Sharma, Thomas A. Paul, Jay H. Chung et al.|Cancer Research|2021Cited by 1